[Recommendations by the Pediatric and Adolescent Rheumatology Study Committee on therapy with Etanercept (p75 TNF-alpha receptor immunoglobulin fusion protein. Pharmacotherapy Committee].
Horneff
G
G
Universitätsklinik und Poliklinik für Kinder- und Jugendmedizin, Martin-Luther-Universität Halle-Wittenberg 06120 Halle. gerd.horneff@medizin.uni-halle.de
Forster
J
J
Seyberth
H W
HW
Michels
H
H
D000293:Adolescent; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D002648:Child; D003131:Combined Modality Therapy; D000075202:Contraindications; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept
Empfehlungen der Arbeitsgemeinschaft Kinder- und Jugendrheumatologie zur Therapie mit Etanercept (P75 TNF-alpha-Rezeptor-Immunglobulinfusionsprotein). Kommission Pharmakotherapie.